Chemours's stock plunges on news that accounting issues are much worse than first thought
By Tomi Kilgore
Chemical company puts its CEO, CFO and chief accounting officer on leave and delays earnings report again
Shares of Chemours Co. were suffering a record selloff Thursday as investors learned that the accounting issues they were made aware of two weeks ago were much worse than they had realized.
The issues were bad enough that the specialty materials and chemicals company said it placed its chief executive, chief financial officer and principal accounting officer on administrative leave pending an internal investigation into accounting practices and controls.
As a result of the investigation, the company said it needed to again delay the release of its fourth-quarter results and to push back the filing of its annual report.
The stock (CC) dropped 31.6% in afternoon trading, toward the lowest close since September 2020. It was also on pace for the biggest one-day selloff since it was spun off from DuPont de Nemours Inc. (DD) in July 2015.
On Feb. 13, the stock tumbled 12.6% after the company said it would have to postpone the reporting of fourth-quarter results by two weeks while it evaluated its financial-reporting controls.
The internal review, overseen by the company's audit committee and with help from outside counsel, includes a look at reports made to the Chemours ethics hotline, practices for managing working capital related to impacts to executive incentive plans, "one or more potential material weaknesses" in controls over financial reporting and the "tone at the top" set by senior management.
Meanwhile, CEO Mark Newman, CFO Jonathan Lock and PAO Camela Wisel were placed on leave. Chemours said it named Denise Dignam, the current president of the Titanium Technologies unit, as interim CEO and current Chief Enterprise Transformation Officer Matt Abbott as interim CFO.
Separately, the company said it expects to report that it swung to a net loss for the year of $225 million to $235 million, from net income of $578 million. The 2023 results included $746 million in litigation settlements and $153 million in restructuring charges, as well as a $106 million gain from the sale of its glycolic acid business.
Read more about Chemours' litigation settlements.
Chemours added that it expects to report 2023 net sales that fell 12% from 2022 to $6 billion. The current FactSet consensus is for $6.07 billion.
Chemours's stock has slumped 37.7% year to date, while the Materials Select Sector SPDR exchange-traded fund XLB has gained 2.5% and the S&P 500 index SPX has tacked on 6.7%.
-Tomi Kilgore
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
02-29-24 1546ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now